“Projecting continued weight loss is expected as the study continues through week sixty-four.”

In context

“s of other weight loss. For the low and medium dose regimens, we see excellent concordance between our VESPA three clinical data in blue and our model predictions in teal. Applying the same model to project the potential efficacy of the planned phase three high dose regimen of 9.6 milligrams monthly, we predict placebo-adjusted weight loss of nearly 16% at week twenty-eight. Note the high dose is already being studied in the Vespa four phase three study as a 2.4 milligram weekly dose. Collectively, our clinical data model predicts show that 3944 can deliver robust weight loss after switching to monthly administration and suggest that we can potentially achieve increased efficacy with a higher dose. Moreover, VESPER three data do not show a weight loss plateau reached at week twenty-eight. Projecting continued weight loss is expected as the study continues through week sixty-four. With these results, we are confident that 3944 has the potential to deliver efficacy that is competitive with the standard of care and potentially best in class among monoagonists with a differentiated monthly dosing format. Chris Boshoff: Next, I'll turn your attention to the second objective of BESPA three, demonstrating a well-tolerated and favorable safety profile for 3944 when switching to a fourfold equivalent monthly dose. Similar to our first objective, I'm pleased to report that year two 3944 delivered. In Vespa three, 3944 displayed a well-tolerated and favorable safety profile that is consistent with what has been observed with weekly GLP-1 receptor agonists. Observed gastrointestinal treatment-emergent adverse events were predominantly mild or moderate, with no more than one i”